Recent Progress in the Research of Small Molecule HIV-1 RNase H Inhibitors
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Reverse transcription of human immunodeficiency virus type 1 (HIV-1) is a crucial step in the life cycle initiated by the viral-coded reverse transcriptase (RT), functioning as RNA- and DNA-dependent DNA polymerase (RDDP and DDDP) and the ribonuclease H (RNase H). The RNase H functions to degrade the RNA strand of the RNA:DNA heteroduplex, which makes it an attractive target for rational anti-HIV-1 drug design and development. Although development of drugs targeting the DNA polymerase have been highly successful, the discovery of drugable inhibitors of HIV RNase H is still in its infancy and none of RNase H inhibitors has reached the clinical development stage currently. This review describes the recent progress in the HIV-1 RNase H inhibitors, focusing on their chemical feature, mechanism and the structure-activity relationship (SAR).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“During the past several years, significant progress has been made in the development of active-site RNH inhibitors [32-35].”
From Retroviral RNase H: structure, mechanism, and inhibition (2021) · cites this paper as [33]
Citations
Cites
Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor
Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A., & Steitz, T. A. (1992) · Science · doi:10.1126/science.1377403 · Cited by 1,914 · cited 1×
“The first 440 residues of p66 and p51 are identical, and in both subunits, these residues comprise four subdomains, termed “finger”, “palm”, “thumb” and “connection” [3].”
BackgroundHuang, H., Chopra, R., Verdine, G. L., & Harrison, S. C. (1998) · Science · doi:10.1126/science.282.5394.1669 · Cited by 1,420
Nowotny, M., Gaidamakov, S. A., Crouch, R. J., & Yang, W. (2005) · Cell · doi:10.1016/j.cell.2005.04.024 · Cited by 620 · cited 2×
“halodurans and human RNase H with bound substrates strongly support the two-metal ion mechanism for HIV-1 RNase H catalysis [6, 13].”
BackgroundShifting from the single to the multitarget paradigm in drug discovery
Medina-Franco, J. L., Giulianotti, M. A., Welmaker, G. S., & Houghten, R. A. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.01.008 · Cited by 483
Structure of Human RNase H1 Complexed with an RNA/DNA Hybrid: Insight into HIV Reverse Transcription
Nowotny, M., Gaidamakov, S. A., Ghirlando, R., Cerritelli, S. M., Crouch, R. J., & Yang, W. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.08.015 · Cited by 316
DNA Aptamers Derived from HIV-1 RNase H Inhibitors are Strong Anti-integrase Agents
de Soultrait, V. R., Lozach, P., Altmeyer, R. M., Tarrago‐Litvak, L., Litvak, S., & Andréola, M. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01064-1 · Cited by 165
Klumpp, K. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg881 · Cited by 151
RNase H activity: structure, specificity, and function in reverse transcription
Schultz, S. J., & Champoux, J. J. (2008) · Virus Research · doi:10.1016/j.virusres.2007.12.007 · Cited by 150 · cited 1×
“The internal cleavage does not require positioning by a DNA 3’-end or an RNA 5’-end: the RNase H acts as a typical endonuclease and the position of cleavage is directed by the certain nucleotide sequence [11].”
BackgroundBillamboz, M., Bailly, F., Lion, C. J., Touati, N., Vezin, H., Calmels, C., Andréola, M., Christ, F., Debyser, Z., & Cotelle, P. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1014692 · Cited by 147
Use of a Pharmacophore Model To Discover a New Class of Influenza Endonuclease Inhibitors
Parkes, K. E. B., Ermert, P., Fässler, J., Ives, J. A. L., Martin, J. A., Merrett, J. H., Obrecht, D., Williams, G., & Klumpp, K. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020334u · Cited by 147
Cited by
Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends: Miniperspective
Zhan, P., Pannecouque, C., De Clercq, E., & Liu, X. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00497 · Cited by 303
Self-citationTargeting Metalloenzymes for Therapeutic Intervention
Chen, A. Y., Adamek, R. N., Dick, B. L., Credille, C. V., Morrison, C. N., & Cohen, S. M. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00201 · Cited by 270
Overview of Recent Strategic Advances in Medicinal Chemistry
Wu, G., Zhao, T., Kang, D., Zhang, J., Song, Y., Namasivayam, V., Kongsted, J., Pannecouque, C., De Clercq, E., Poongavanam, V., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00359 · Cited by 181
Self-citationCatalytic Metal Ions and Enzymatic Processing of DNA and RNA
Palermo, G., Cavalli, A., Klein, M. L., Alfonso-Prieto, M., Dal Peraro, M., & De Vivo, M. (2015) · Accounts of Chemical Research · doi:10.1021/ar500314j · Cited by 170
Avoiding drug resistance in HIV reverse transcriptase
Cilento, M. E., Kirby, K. A., & Sarafianos, S. G. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00967 · Cited by 106
Metadata
- Authors
- Cao, L., Song, W., Clercq, E., Zhan, P., & Liu, X.
- Affiliations
- Shandong University (CN)
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2014-04
- Volume
- 21
- Issue
- 17
- Pages
- 1956-1967
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2129701380
- Cited by
- 34
- References
- 43
- Citations by year
- 2024: 2 · 2022: 4 · 2021: 3 · 2020: 2 · 2019: 3 · 2018: 8 · 2017: 3 · 2016: 4 · 2015: 4 · 2014: 1
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Lirias (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- HIV-1, RNase H inhibitors, reverse transcription, reverse transcriptase, RNA-DNA heteroduplex, small molecule inhibitors, structure-activity relationship, anti-HIV drug design, DNA-dependent DNA polymerase
- MeSH terms
- Humans, Models, Molecular, Structure-Activity Relationship, Drug Design, HIV-1, HIV Infections, Anti-HIV Agents, Ribonuclease H, Human Immunodeficiency Virus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Progress in the Research of Small Molecule HIV-1 RNase H Inhibitors. https://app.cochat.ai/papers/10.2174/0929867321666140120121158
- The paper
- Cao, L., Song, W., Clercq, E., Zhan, P., & Liu, X. (2014). Recent Progress in the Research of Small Molecule HIV-1 RNase H Inhibitors. Current Medicinal Chemistry. https://doi.org/10.2174/0929867321666140120121158
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.